menu
    • menu

    Company profile for Amylyx Pharmaceuticals

    NEW Drugs in Dev: 4
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Amylyx is developing AMX0035 to improve the lives of people living with ALS, Alzheimer’s and other diseases of the brain. AMX0035 is a drug designed to prevent nerve cell death and degeneration. The drug improved cellular metabolism and promoted protein folding in cellular and animal models of neurodegenerative disease. When metabolism and protein folding are not functioning properly, neurons halt key functions and ultimatel...
    Amylyx is developing AMX0035 to improve the lives of people living with ALS, Alzheimer’s and other diseases of the brain. AMX0035 is a drug designed to prevent nerve cell death and degeneration. The drug improved cellular metabolism and promoted protein folding in cellular and animal models of neurodegenerative disease. When metabolism and protein folding are not functioning properly, neurons halt key functions and ultimately can die. Metabolism and protein folding appear to be dysfunctional in ALS, Alzheimer’s and other neurological diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Amylyx PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    43 Thorndike St., Cambridge MA 02141
    Telephone
    Telephone
    +1 617-682-0917
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.amylyx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/amylyx/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/amylyxpharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASCO GU

    ASCO GU

    Not Confirmed

    envelop Contact Supplier

    ASCO GU

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amylyx Pharma to Report Q4, FY 2025 Results on March 3, 2026
    Amylyx Pharma to Report Q4, FY 2025 Results on March 3, 2026

    24 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260224052667/en/Amylyx-Pharmaceuticals-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-March-3-2026

    BUSINESSWIRE
    24 Feb 2026
    Share Share
    Amylyx Pharma Nominates Gubra's AMX0318 as GLP-1RA Candidate
    Amylyx Pharma Nominates Gubra's AMX0318 as GLP-1RA Candidate

    08 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260108102624/en/Amylyx-Pharmaceuticals-Announces-Nomination-of-AMX0318-as-a-Novel-Long-Acting-GLP-1-Receptor-Antagonist-Development-Candidate-Identified-in-Collaboration-with-Gubra-AS

    BUSINESSWIRE
    08 Jan 2026
    Share Share
    Amylyx Pharma Reveals AMX0114 Safety Data In ALS Trial
    Amylyx Pharma Reveals AMX0114 Safety Data In ALS Trial

    05 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251205363745/en/Amylyx-Pharmaceuticals-Announces-New-Safety-and-Tolerability-Cohort-1-Data-of-AMX0114-in-ALS-from-First-in-Human-LUMINA-Trial

    BUSINESSWIRE
    05 Dec 2025
    Share Share
    Amylyx Pharma Reveals Q3 2025 Financials
    Amylyx Pharma Reveals Q3 2025 Financials

    06 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251106437649/en/Amylyx-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results

    BUSINESSWIRE
    06 Nov 2025
    Share Share
    Amylyx Pharma To Present at Investor Conferences
    Amylyx Pharma To Present at Investor Conferences

    03 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251103271379/en/Amylyx-Pharmaceuticals-to-Present-at-Upcoming-Investor-Conferences

    BUSINESSWIRE
    03 Nov 2025
    Share Share
    Amylyx Pharma to Release Q3 2025 Financial Results on Nov 6
    Amylyx Pharma to Release Q3 2025 Financial Results on Nov 6

    30 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251030438814/en/Amylyx-Pharmaceuticals-to-Report-Third-Quarter-2025-Financial-Results-on-November-6-2025

    BUSINESSWIRE
    30 Oct 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search